Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome

Pereira-Azevedo, Nuno; Verbeek, J.; Nieboer, D.; Bangma, C.; Roobol, M.

Publication

Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome

2018-02Journal article

dc.contributor.author	Pereira-Azevedo, Nuno
dc.contributor.author	Verbeek, J.
dc.contributor.author	Nieboer, D.
dc.contributor.author	Bangma, C.
dc.contributor.author	Roobol, M.
dc.date.accessioned	2020-03-24T11:21:12Z
dc.date.available	2020-03-24T11:21:12Z
dc.date.issued	2018-02
dc.description.abstract	Background: Multivariable risk calculators (RCs) predicting prostate cancer (PCa) aim to reduce unnecessary workup (e.g., MRI and biopsy) by selectively identifying those men at risk for PCa or clinically significant PCa (csPCa) (Gleason ≥7). The lack of an adequate comparison makes choosing between RCs difficult for patients, clinicians and guideline developers. We aim to perform a head-to-head comparison of seven well known RCs predicting biopsy outcome. Methods: Our study comprised 7,119 men from ten independent contemporary cohorts in Europe and Australia, who underwent prostate biopsy between 2007 and 2015. We evaluated the performance of the ERSPC RPCRC, Finne, Chun, ProstataClass, Karakiewicz, Sunnybrook, and PCPT 2.0 (HG) RCs in predicting the presence of any PCa and csPCa. Performance was assessed by discrimination, calibration and net benefit analyses. Results: A total of 3,458 (48%) PCa were detected; 1,784 (25%) men had csPCa. No particular RC stood out predicting any PCa: pooled area under the ROC-curve (AUC) ranged between 0.64 and 0.72. The ERSPC RPCRC had the highest pooled AUC 0.77 (95% CI: 0.73-0.80) when predicting csPCa. Decision curve analysis (DCA) showed limited net benefit in the detection of csPCa, but that can be improved by a simple calibration step. The main limitation is the retrospective design of the study. Conclusions: No particular RC stands out when predicting biopsy outcome on the presence of any PCa. The ERSPC RPCRC is superior in identifying those men at risk for csPCa. Net benefit analyses show that a multivariate approach before further workup is advisable.	pt_PT
dc.description.version	info:eu-repo/semantics/publishedVersion	pt_PT
dc.identifier.citation	Pereira-Azevedo N, Verbeek JFM, Nieboer D, Bangma CH, Roobol MJ. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome. Transl Androl Urol. 2018;7(1):18–26. doi:10.21037/tau.2017.12.21	pt_PT
dc.identifier.doi	10.21037/tau.2017.12.21	pt_PT
dc.identifier.issn	2223-4691
dc.identifier.issn	2223-4683
dc.identifier.uri	http://hdl.handle.net/10400.16/2342
dc.language.iso	eng	pt_PT
dc.peerreviewed	yes	pt_PT
dc.publisher	AME Pub	pt_PT
dc.relation.publisherversion	http://tau.amegroups.com/article/view/18152/18433	pt_PT
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	pt_PT
dc.subject	Prostate biopsy	pt_PT
dc.subject	overdiagnosis	pt_PT
dc.subject	prostate cancer (PCa)	pt_PT
dc.subject	prostate-specific antigen (PSA)	pt_PT
dc.subject	risk calculators (RCs)	pt_PT
dc.title	Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome	pt_PT
dc.type	journal article
dspace.entity.type	Publication
oaire.citation.conferencePlace	China	pt_PT
oaire.citation.endPage	26	pt_PT
oaire.citation.issue	1	pt_PT
oaire.citation.startPage	18	pt_PT
oaire.citation.title	Translational andrology and urology	pt_PT
oaire.citation.volume	7	pt_PT
person.familyName	Pereira Azevedo
person.givenName	Nuno
person.identifier.ciencia-id	6710-0370-1173
person.identifier.orcid	0000-0002-0442-6565
rcaap.rights	openAccess	pt_PT
rcaap.type	article	pt_PT
relation.isAuthorOfPublication	30b39606-0b49-43d6-b03a-afe11752f3a0
relation.isAuthorOfPublication.latestForDiscovery	30b39606-0b49-43d6-b03a-afe11752f3a0